Sermonix Pharmaceuticals awarded U.S. patent for lasofoxifene in breast cancer treatment
Sermonix Pharmaceuticals Inc., a leader in biopharmaceutical innovations, has achieved a significant milestone with the issuance of a new U.S. patent that broadens the application of its leading investigational drug, lasofoxifene. The patent, officially recorded as U.S. Patent No. 12,023,321 B2, introduces a novel method for treating estrogen receptor-positive (ER+) breast cancer that is resistant […]